Related Content

One of the largest research awards made to the University just got bigger. It’s not only UNC’s largest project in global health, but the largest single award the University has ever received, at $231.9 million....

The University has received a funding boost for its research in the Galápagos Islands and work elsewhere in the world, including in Hawaii and Puerto Rico. The NASA Land Cover/Land Use Change Program has a...

For the first time, the University’s annual research expenditures have surpassed $1 billion, $632 million of which are sponsored by federal government agencies, notably the National Institutes of Health. The figures, reported via the nation’s...

Researchers Get $11.3 Million Grant to Study Nanotechnology in Fighting Cancer

UNC researchers will use an $11.3 million grant to explore using nanoparticles to create cancer vaccines and improve delivery of cancer-fighting drugs and patients’ responses to them.

The five-year grant announced Monday is the third in a series of awards that the University has won from the National Cancer Institute for cancer nanotechnology research. It will fund researchers with the Carolina Center of Cancer Nanotechnology Excellence, an institute-funded collaboration between the University and the UNC Lineberger Comprehensive Cancer Center.

“UNC-Chapel Hill has emerged as a leader in nanotechnology in the last 10 years,” said Leaf Huang, a UNC Lineberger member, Fred Eshelman Distinguished Professor and interim chair of the UNC Eshelman School of Pharmacy Division of Molecular Therapeutics, and the co-leader of the cancer nanotechnology center. “This grant is a testament to the quality of our research in using nanotechnology to continue to find innovative ways to fight cancer.”

The grant will fund four studies of nanotechnology in fighting cancer:

Creating a vaccine that would train the body’s immune system to recognize and fight drug-resistant melanoma.

Developing a vaccine for advanced melanoma. The concept is to use nanoparticles to deliver drugs targeting molecules in the tumor’s microenvironment that would help immune cells destroy cancerous cells.